https://www.marketscreener.com/quote/stock/GENMAB-A-S-63733191/news/Genmab-and-Seagen-Announce-That-TIVDAK-tisotumab-vedotin-tftv-Met-its-Primary-Endpoint-of-Improv-44766580/?utm_source=telegram&utm_medium=social&utm_campaign=share